[Pathogenesis of lymphoreticular neoplasms in transplant recipients].
D000818:Animals; D000961:Antilymphocyte Serum; D002471:Cell Transformation, Neoplastic; D006648:Histocompatibility; D006801:Humans; D007165:Immunosuppression Therapy; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D008223:Lymphoma / Q000209:etiology* / Q000276:immunology / Q000473:pathology; D008228:Lymphoma, Non-Hodgkin / Q000139:chemically induced; D051379:Mice; D010672:Phenytoin / Q000009:adverse effects; D013160:Splenic Neoplasms / Q000139:chemically induced; D014181:Transplantation Immunology
D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents; D010672:Phenytoin
Zur Pathogenese von Tumoren des lymphoretikulären Gewebes bei Transplantatemfängern.